期刊文献+

非布司他在高尿酸血症伴慢性肾病患者中的药代动力学及药效评价 被引量:3

下载PDF
导出
摘要 目的评价在高尿酸血症伴慢性肾病患者中应用非布司他的药代动力学及药效。方法选取2013年5月至2015年2月期间在我院通过血液透析治疗高尿酸血症伴慢性肾病患者21例,将其随机分为甲、乙、丙三组,每组各7例患者,三组患者分别行空腹单次口服40 mg、80 mg、120 mg的非布司他片,乙组结束单次药物试验后,继续空腹口服80 mg的非布司他片,1次/天,疗程为28 d,测定血浆中非布司他的浓度的方法为LC-MS/MS法,血清尿酸值采用全自动生化分析仪测定。结果经过治疗后,高尿酸血症伴慢性肾病患者的血尿酸水平均明显下降,治疗效果明显;在药代动力学方面,空腹单次口服40 mg、80 mg、120 mg的非布司他片的主要药代动力学参数包括:t1/2不同剂量分别为(3.76±1.38)h、(4.57±1.25)h、(4.31±1.30)h.C max分别为(1628.24±353.88)ng/m L、(2671.24±385.16)ng/m L、(3911.76±837.11)ng/m L,AUC0-24分别为(4316.28±980.37)、(8412.35±1970.37)、(12983.55±3791.62)ng/(m L·h),患者的体内无蓄积,药物吸收程度和速度无变化,在治疗中有1例出现轻微的皮疹反应,2例患者出现轻微的头痛以及嗜睡现象,停药后,症状自行消失。结论40~120 mg非布司他单次空腹口服其药代动力学呈线性,在治疗高尿酸血症伴慢性肾病中效果明显。
作者 王晓娜
出处 《中国医药指南》 2017年第12期58-59,共2页 Guide of China Medicine
  • 相关文献

参考文献4

二级参考文献42

  • 1Takano Y,Hase-Aoki K,Horiuchi H,et al.Selectivity of febuxostat,a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci,2005,76(16):1835-1847.
  • 2Bruce SP.Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Ann Pharmacother,2006,40(12):2187-2194.
  • 3Mayer MD,Khosravan R,Vernillet L,et al.Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.Am J Ther,2005,12(1):22-34.
  • 4Khosravan R,Grabowski BA,Wu JT,et al.Pharmacokinetics,pharmacodynamics and safety of febuxostat,a non-purine selective inhibitor of xanthine oxidase,in a dose escalation study in healthy subjects.Clin Pharmacokinet,2006,45(8):821-841.
  • 5Khosravan R,Grabowski BA,Mayer MD,et al.The effect of mild and moderate hepatic impairment on pharmacokinetics,pharmacodynamics,and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase.J Clin Pharmacol,2006,46(1):88-102.
  • 6Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day,multicenter,phaseⅡ,randomized,double-blind,placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout.Arthritis Rheum,2005,52(3):916-923.
  • 7Schumacher HR,Becker MA,Wortmann RL,et al.Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial.Arthritis Rheum,2008,59(11):1540-1548.
  • 8Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.N Engl J Med,2005,353(23):2450-2461.
  • 9Becker MA,Schumacher HR,Espinoza LR,et al.The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout:the CONFIRMS trial.Arthritis Res Ther,2010,12(2):R63.
  • 10Schumacher HR,Becker MA,Lloyd E,et al.Febuxostat in the treatment of gout:5-yr findings of the FOCUS efficacy and safety study.Rheumatology (Oxford),2009,48(2):188-194.

共引文献124

同被引文献18

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部